AFP and hepatocellular carcinoma: In conclusion, the present study is the first to demonstrate that serum L-glu and PA are upregulated in MetS(+) HCC patients, and biomarker panel including L-glu, PA and AFP exhibits good diagnostic performance for discriminating MetS(+) HCC from MetS patients.